Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab

Cancers

Bernhard Volz¹  Erik Belleville²  Christian Kurbacher³  Rachel Wuerstlein⁴  Pauline Wimberger⁵  TanjaN. Fehm⁶  Hanna Huebner⁷  PeterA. Fasching⁷  Lothar Häberle⁷  MatthiasW. Beckmann⁷  Markus Wallwiener⁸  LauraL. Michel⁸  Michael Untch⁹  Christoph Mundhenke^1,10  Hans-Christian Kolberg^1,11  Wolfgang Janni^1,12  Jens Huober^1,12  Volkmar Müller^1,13  Florin-Andrei Taran^1,14  Diana Lüftner^1,15  Johannes Ettl^1,16  Diethelm Wallwiener^1,17  AndreasD. Hartkopf^1,17  SaraY. Brucker^1,17  Peyman Hadji^1,18  MichaelP. Lux^1,19  Andreas Schneeweiss^2,20  Friedrich Overkamp^2,21  Hans Tesch^2,22  Carsten Hielscher^2,23 

[1] Ansbach University of Applied Sciences, 91522 Ansbach, Germany;ClinSol GmbH & Co KG, 97074 Würzburg, Germany;Department of Gynecology I (Gynecologic Oncology), Gynecologic Center Bonn-Friedensplatz, 53111 Bonn, Germany;Department of Gynecology and Obstetrics, Breast Center and CCC Munich, Munich University Hospital, 81377 Munich, Germany;Department of Gynecology and Obstetrics, Carl Gustav Carus Faculty of Medicine and University Hospital, Technical University of Dresden, 01307 Dresden, Germany;Department of Gynecology and Obstetrics, Düsseldorf University Hospital, 40225 Düsseldorf, Germany;Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, 91054 Erlangen, Germany;Department of Gynecology and Obstetrics, Heidelberg University Hospital, 69120 Heidelberg, Germany;Department of Gynecology and Obstetrics, Helios Clinics Berlin-Buch, 13125 Berlin, Germany;Department of Gynecology and Obstetrics, Klinik Hohe Warte, 95445 Bayreuth, Germany;Department of Gynecology and Obstetrics, Marienhospital Bottrop, 46236 Bottrop, Germany;Department of Gynecology and Obstetrics, Ulm University Hospital, 89075 Ulm, Germany;Department of Gynecology, Hamburg-Eppendorf University Medical Center, 20246 Hamburg, Germany;Department of Gynecology, Zurich University Hospital, 8091 Zurich, Switzerland;Department of Hematology, Oncology and Tumor Immunology, Charité University Hospital, Campus Benjamin Franklin, 12203 Berlin, Germany;Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany;Department of Obstetrics and Gynecology, University of Tübingen, 72076 Tübingen, Germany;Frankfurt Center for Bone Health, 60313 Frankfurt am Main, Germany;Kooperatives Brustzentrum Paderborn, Department of Gynecology and Obstetrics, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, 33098 Paderborn, Germany;National Center for Tumor Diseases, Heidelberg University Hospital, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany;OncoConsult Overkamp GmbH, 10557 Berlin, Germany;Oncology Practice, Bethanien Hospital, 60389 Frankfurt am Main, Germany;g.SUND Gynäkologie-Onkologisches Zentrum, 18435 Stralsund, Germany;

关键词: advanced breast cancer;    metastatic;    chemotherapy;    HER2 c-erbB2;    HER2/neu;    trastuzumab;   

DOI  :  10.3390/cancers12103021

来源: DOAJ

【 摘 要 】

The approval of trastuzumab emtansine (T-DM1) was conducted without pertuzumab as previous therapy. Efficacy data on T-DM1 following pertuzumab treatment are therefore limited. This study explores this issue in a real-world setting. Within the prospective PRAEGNANT (Prospective Academic Translational Research Network for the Optimization of the Oncological Health Care Quality in the Advanced Setting) metastatic breast cancer registry (NCT02338167), patients in all therapy lines receiving any kind of treatment were eligible for inclusion. This report describes patient characteristics and progression-free survival (PFS) in human epidermal growth factor receptor 2 (HER2)-positive patients receiving T-DM1 after pertuzumab treatment. Seventy-six patients were identified, 39 of whom received T-DM1 as second-line therapy, 25 as third-line, and 12 as fourth-line therapy or higher. Pertuzumab was mostly administered as a first-line treatment (n = 61; 80.3%). The median PFS in all patients was 3.5 months (95% CI: 2.8–7.8); in second-line treatment, 7.7 months (95% CI: 2.8–11.0); in third-line, 3.4 months (95% CI: 2.3–not reached (NR)); and in fourth-line therapy or higher, 2.7 months (95% CI: 1.2–NR). T-DM1 was mainly administered second-line after pertuzumab, but also in more heavily pretreated patients. The PFS in higher therapy lines appears to be shorter than in second-line.

【 授权许可】

Unknown